ALDX Relative Valuation
ALDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALDX is overvalued; if below, it's undervalued.
Historical Valuation
Aldeyra Therapeutics Inc (ALDX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 9.61 is considered Overvalued compared with the five-year average of -14.89. The fair price of Aldeyra Therapeutics Inc (ALDX) is between 1.49 to 3.76 according to relative valuation methord. Compared to the current price of 4.11 USD , Aldeyra Therapeutics Inc is Overvalued By 9.21%.
Relative Value
Fair Zone
1.49-3.76
Current Price：4.11
9.21%
Overvalued
-8.87
PE
1Y
3Y
5Y
0.00
EV/EBITDA
Aldeyra Therapeutics Inc. (ALDX) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -3.93. The thresholds are as follows: Strongly Undervalued below -10.47, Undervalued between -10.47 and -7.20, Fairly Valued between -0.65 and -7.20, Overvalued between -0.65 and 2.62, and Strongly Overvalued above 2.62. The current Forward EV/EBITDA of 0.00 falls within the Overvalued range.
-26.81
EV/EBIT
Aldeyra Therapeutics Inc. (ALDX) has a current EV/EBIT of -26.81. The 5-year average EV/EBIT is -6.65. The thresholds are as follows: Strongly Undervalued below -20.54, Undervalued between -20.54 and -13.60, Fairly Valued between 0.29 and -13.60, Overvalued between 0.29 and 7.24, and Strongly Overvalued above 7.24. The current Forward EV/EBIT of -26.81 falls within the Strongly Undervalued range.
9.61
PS
Aldeyra Therapeutics Inc. (ALDX) has a current PS of 9.61. The 5-year average PS is 21.33. The thresholds are as follows: Strongly Undervalued below -57.50, Undervalued between -57.50 and -18.09, Fairly Valued between 60.74 and -18.09, Overvalued between 60.74 and 100.16, and Strongly Overvalued above 100.16. The current Forward PS of 9.61 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Aldeyra Therapeutics Inc. (ALDX) has a current P/OCF of 0.00. The 5-year average P/OCF is -6.03. The thresholds are as follows: Strongly Undervalued below -16.26, Undervalued between -16.26 and -11.15, Fairly Valued between -0.92 and -11.15, Overvalued between -0.92 and 4.20, and Strongly Overvalued above 4.20. The current Forward P/OCF of 0.00 falls within the Overvalued range.
0.00
P/FCF
Aldeyra Therapeutics Inc. (ALDX) has a current P/FCF of 0.00. The 5-year average P/FCF is -5.48. The thresholds are as follows: Strongly Undervalued below -12.45, Undervalued between -12.45 and -8.96, Fairly Valued between -2.00 and -8.96, Overvalued between -2.00 and 1.49, and Strongly Overvalued above 1.49. The current Forward P/FCF of 0.00 falls within the Overvalued range.
Aldeyra Therapeutics Inc (ALDX) has a current Price-to-Book (P/B) ratio of 5.71. Compared to its 3-year average P/B ratio of 3.40 , the current P/B ratio is approximately 67.73% higher. Relative to its 5-year average P/B ratio of 3.15, the current P/B ratio is about 81.02% higher. Aldeyra Therapeutics Inc (ALDX) has a Forward Free Cash Flow (FCF) yield of approximately -14.27%. Compared to its 3-year average FCF yield of -14.86%, the current FCF yield is approximately -3.96% lower. Relative to its 5-year average FCF yield of -14.04% , the current FCF yield is about 1.65% lower.
5.71
P/B
Median3y
3.40
Median5y
3.15
-14.27
FCF Yield
Median3y
-14.86
Median5y
-14.04
Competitors Valuation Multiple
The average P/S ratio for ALDX's competitors is 3.24, providing a benchmark for relative valuation. Aldeyra Therapeutics Inc Corp (ALDX) exhibits a P/S ratio of 9.61, which is 196.61% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ALDX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ALDX in the past 1 year is driven by Unknown.
People Also Watch
AQST
Aquestive Therapeutics Inc
6.21USD
-0.32%
ELMD
Electromed Inc
29.02USD
-1.29%
RZLT
Rezolute Inc
2.37USD
0.85%
BRBS
Blue Ridge Bankshares Inc
4.35USD
1.87%
DOMO
Domo Inc
8.15USD
-5.12%
RGP
Resources Connection Inc
4.5USD
-14.61%
SMTI
Sanara Medtech Inc
25.07USD
2.79%
DSGN
Design Therapeutics Inc
9.18USD
-6.99%
AVIR
Atea Pharmaceuticals Inc
3.61USD
3.74%
FPH
Five Point Holdings LLC
5.81USD
2.65%
Frequently Asked Questions
Is Aldeyra Therapeutics Inc (ALDX) currently overvalued or undervalued?
Aldeyra Therapeutics Inc (ALDX) is now in the Overvalued zone, suggesting that its current forward PS ratio of 9.61 is considered Overvalued compared with the five-year average of -14.89. The fair price of Aldeyra Therapeutics Inc (ALDX) is between 1.49 to 3.76 according to relative valuation methord. Compared to the current price of 4.11 USD , Aldeyra Therapeutics Inc is Overvalued By 9.21% .
What is Aldeyra Therapeutics Inc (ALDX) fair value?
ALDX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Aldeyra Therapeutics Inc (ALDX) is between 1.49 to 3.76 according to relative valuation methord.
How does ALDX's valuation metrics compare to the industry average?
The average P/S ratio for ALDX's competitors is 3.24, providing a benchmark for relative valuation. Aldeyra Therapeutics Inc Corp (ALDX) exhibits a P/S ratio of 9.61, which is 196.61% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Aldeyra Therapeutics Inc (ALDX) as of Jan 09 2026?
As of Jan 09 2026, Aldeyra Therapeutics Inc (ALDX) has a P/B ratio of 5.71. This indicates that the market values ALDX at 5.71 times its book value.
What is the current FCF Yield for Aldeyra Therapeutics Inc (ALDX) as of Jan 09 2026?
As of Jan 09 2026, Aldeyra Therapeutics Inc (ALDX) has a FCF Yield of -14.27%. This means that for every dollar of Aldeyra Therapeutics Inc’s market capitalization, the company generates -14.27 cents in free cash flow.
What is the current Forward P/E ratio for Aldeyra Therapeutics Inc (ALDX) as of Jan 09 2026?
As of Jan 09 2026, Aldeyra Therapeutics Inc (ALDX) has a Forward P/E ratio of -8.87. This means the market is willing to pay $-8.87 for every dollar of Aldeyra Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Aldeyra Therapeutics Inc (ALDX) as of Jan 09 2026?
As of Jan 09 2026, Aldeyra Therapeutics Inc (ALDX) has a Forward P/S ratio of 9.61. This means the market is valuing ALDX at $9.61 for every dollar of expected revenue over the next 12 months.